[摘要] 目的 探討甘精胰島素聯(lián)合瑞格列奈治療2型糖尿病的治療效果。 方法 選擇我院2016年3月～2017年6月間收治的2型糖尿病患者72例作為研究對(duì)象，按照電腦隨機(jī)數(shù)分組的方案，將其隨機(jī)分為兩組，分別為對(duì)照組和實(shí)驗(yàn)組，每組36例患者。對(duì)照組患者采用單純預(yù)混胰島素進(jìn)行治療，而實(shí)驗(yàn)組患者則應(yīng)用甘精胰島素聯(lián)合瑞格列奈進(jìn)行治療。對(duì)比兩組患者的治療效果，記錄兩組患者的空腹血糖（FPG）、餐后2 h血糖（2hPG）、糖化血紅蛋白（HbA1c）的數(shù)值，分析治療效果。 結(jié)果 實(shí)驗(yàn)結(jié)果顯示，實(shí)驗(yàn)組患者的治療總有效率較對(duì)照組明顯更高，差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。兩組患者在治療完成后，各項(xiàng)指標(biāo)數(shù)據(jù)均有所改善，但實(shí)驗(yàn)組患者改善程度較對(duì)照組明顯更優(yōu)，差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。 結(jié)論 應(yīng)用甘精胰島素聯(lián)合瑞格列奈對(duì)2型糖尿病患者進(jìn)行治療能夠有效提高患者的治療效果，緩解患者的臨床癥狀，控制患者的各項(xiàng)血糖指標(biāo)水平，具有較好的治療效果，值得在臨床上推廣使用。
　　[關(guān)鍵詞] 甘精胰島素；瑞格列奈；2型糖尿病
　　[中圖分類號(hào)] R587.1 [文獻(xiàn)標(biāo)識(shí)碼] B [文章編號(hào)] 1673-9701（2018）08-0042-03
　　Curative effect observation of treatment combining insulin glargine and repaglinide in patients with type-2 diabetes
　　WANG Yuanfang
　　Department of Internal Medicine， Zaozhuang Hospital of Zaozhuang Mining Group， Zaozhuang 277100， China
　　[Abstract] Objective To investigate the curative effect of treatment combining insulin glargine and repaglinide in patients with type-2 diabetes. Methods 72 patients with tyepe-2 diabetes in our hospital from March 2016 to June 2017 were selected and randomized into control group and study group according to grouping schemes generated through computer random number with 36 patients in each. Patients in control group were treated with pure premixed insulin while patients in study group were treated with insulin glargine and repaglinide. The curative effect of patients in two groups was compared. The levels of fasting plasma glucose（FPG）， 2-hour postprandial plasma glucose（2hPG） and glycosylated hemoglobin（HbA1c） in two groups were recorded to assess the curative effect. Results Results of this study showed the overall rate of effectiveness in study group was statistically higher than that in control group（P<0.05）. The status of indicators in patients of both two groups improved whereas the status in study group improved more than control group（P<0.05）. Conclusion Treatment combining insulin glargine and repaglinide in patients with type-2 diabetes could improve the curative effect， relive clinical symptoms and control the levels of blood glucose indicators. The curative effect was good and this treatment was worth clinical promotion.
　　[Key words] Insulin glargine； Repaglinide； Type-2 diabetes
　　2型糖尿病又被稱作為成人發(fā)病型糖尿病[1]。35～40歲人群為2型糖尿病的高發(fā)人群，90%的2型糖尿病患者均在35～40歲發(fā)病[2]。2型糖尿病患者并非產(chǎn)生胰島素的功能完全消失，部分患者甚至?xí)�出現(xiàn)胰島素產(chǎn)生過多的狀況[3]。導(dǎo)致患者血糖升高的主要原因?yàn)橐葝u素的作用、效果較差，所以需要對(duì)患者進(jìn)行胰島素分泌刺激，以保證患者的胰島素供應(yīng)[4]。部分患者甚至需要采用胰島素對(duì)其進(jìn)行治療。
　　1資料與方法
　　1.1一般資料
　　選擇2016年3月～2017年6月間我院收治的2型糖尿病患者72例作為研究對(duì)象，按照電腦隨機(jī)數(shù)分組的方案，將其隨機(jī)分為兩組，分別為對(duì)照組和實(shí)驗(yàn)組，每組36例患者。對(duì)照組男19例，女17例，年齡37～62歲，平均（45.9±8.1）歲；實(shí)驗(yàn)組男18例，女18例，年齡34～62歲，平均（46.1±8.4）歲。兩組患者一般資料比較差異無統(tǒng)計(jì)學(xué)意義（P>0.05），具有可比性。

相關(guān)熱詞搜索：胰島素 療效 糖尿病 臨床 格列